We are live on
!
Find out more
ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
1-Year Est. Return
7.38%
This Fund
S&P 500
This Quarter
Est. Return
+26.16%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$277M
AUM Growth
-$60.9M
(-18%)
Cap. Flow
-$112M
Cap. Flow
% of AUM
-40.48%
Top 10 Holdings %
Top 10 Hldgs %
46.86%
Holding
81
New
21
Increased
12
Reduced
18
Closed
29
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Becton Dickinson
BDX
|
+$16.6M |
| 2 |
Cencora
COR
|
+$7.84M |
| 3 |
Smith & Nephew
SNN
|
+$7.09M |
| 4 |
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
|
+$6.82M |
| 5 |
ACH
Accendra Health
ACH
|
+$5.26M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Encompass Health
EHC
|
+$15M |
| 2 |
Integra LifeSciences
IART
|
+$13.3M |
| 3 |
AdaptHealth
AHCO
|
+$11.4M |
| 4 |
AbbVie
ABBV
|
+$11M |
| 5 |
Bristol-Myers Squibb
BMY
|
+$8.98M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.81% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
OXFD
1
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $39.1M | 14.11% |
2,240,421
+485,956
| +28% | +$6.82M |
|
|
2
Becton Dickinson
BDX
$45.6B
| $17.3M | 6.25% |
+70,996
| New | +$16.6M |
|
|
3
Bristol-Myers Squibb
BMY
$133B
| $15.1M | 5.46% |
244,066
-146,090
| -37% | -$8.98M |
|
|
TRIL
4
DELISTED
Trillium Therapeutics Inc.
TRIL
| $9.65M | 3.48% |
655,741
+283,340
| +76% | +$4.09M |
|
|
5
AbbVie
ABBV
$443B
| $9.06M | 3.27% |
84,544
-114,377
| -57% | -$11M |
|
6
Johnson & Johnson
JNJ
$618B
| $8.85M | 3.19% |
56,231
-18,748
| -25% | -$2.77M |
|
7
OrthoPediatrics
KIDS
$519M
| $7.96M | 2.87% |
193,008
+66,244
| +52% | +$3.04M |
|
|
8
Cencora
COR
$60.6B
| $7.66M | 2.76% |
+78,339
| New | +$7.84M |
|
9
SI-BONE Inc
SIBN
$788M
| $7.62M | 2.75% |
254,907
-208,243
| -45% | -$5.07M |
|
|
10
Smith & Nephew
SNN
$13.3B
| $7.55M | 2.72% |
+179,138
| New | +$7.09M |
|
11
Aclaris Therapeutics
ACRS
$726M
| $7.29M | 2.63% |
1,126,675
-306,142
| -21% | -$1.29M |
|
12
Elevance Health
ELV
$81.5B
| $7.27M | 2.62% |
22,634
+4,725
| +26% | +$1.45M |
|
|
SYNH
13
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $6.95M | 2.51% |
101,953
-10,198
| -9% | -$636K |
|
|
MTEM
14
DELISTED
Molecular Templates, Inc.
MTEM
| $6.4M | 2.31% |
45,416
+17,230
| +61% | +$2.55M |
|
15
Fate Therapeutics
FATE
$286M
| $6.05M | 2.18% |
66,585
+10,375
| +18% | +$644K |
|
|
16
Encompass Health
EHC
$11B
| $6.04M | 2.18% |
91,892
-255,172
| -74% | -$15M |
|
17
Ocular Therapeutix
OCUL
$1.79B
| $6.01M | 2.17% |
290,465
-546,672
| -65% | -$8.12M |
|
|
ADAP
18
DELISTED
Adaptimmune Therapeutics
ADAP
| $5.81M | 2.1% |
1,078,177
+503,675
| +88% | +$2.74M |
|
|
19
AdaptHealth
AHCO
$1.47B
| $5.65M | 2.04% |
150,414
-367,963
| -71% | -$11.4M |
|
20
Elutia
ELUT
$37.9M
| $5.56M | 2.01% |
+408,213
| New | +$5.1M |
|
|
ACH
21
Accendra Health
ACH
$237M
| $5.53M | 1.99% |
+204,384
| New | +$5.26M |
|
22
Avantor
AVTR
$9.32B
| $5.48M | 1.98% |
+194,777
| New | +$5.02M |
|
|
ESPR
23
DELISTED
Esperion Therapeutics
ESPR
| $5.39M | 1.94% |
207,293
+71,392
| +53% | +$2.14M |
|
24
Cigna
CI
$73.7B
| $5.22M | 1.88% |
25,085
-42,376
| -63% | -$8.31M |
|
25
Sarepta Therapeutics
SRPT
$1.57B
| $4.84M | 1.74% |
+28,378
| New | +$4.2M |
|
Similar funds
VAFP
CA
SCM
FWM
TOPU
CCMU
TGI
HSCU
Endurant Capital Management's Q4 2020 Portfolio in Review
As of Q4 2020, Endurant Capital Management held 81 positions worth $277M, down 18% from $338M the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Endurant Capital Management withdrew a net $112M in Q4 2020, closing 29 positions and reducing 18 holdings. Its most notable exit was Integra LifeSciences, an estimated $13.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 83% a quarter earlier.
Against the trend, Endurant Capital Management opened a new position in Becton Dickinson worth $17.3M.
- Endurant Capital Management's largest Q4 2020 buy was Becton Dickinson: 70,996 shares worth $17.3M.
- Endurant Capital Management added most to Oxford Immunotec Global PLC Ordinary Shares in Q4 2020, an estimated $6.82M increase.
- Endurant Capital Management's biggest Q4 2020 reduction was Encompass Health, cutting an estimated $15M.
- Endurant Capital Management fully exited Integra LifeSciences in Q4 2020, selling an estimated $13.3M.
- Endurant Capital Management's ten largest holdings make up 47% of its $277M portfolio in Q4 2020.
- Endurant Capital Management opened 21 new positions and closed 29 in Q4 2020.
- Endurant Capital Management's portfolio value fell 18% quarter-over-quarter to $277M.
Based on Endurant Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.